10 Best Undervalued Healthcare Stocks for January 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The healthcare sector continues to show resilience amid market volatility, driven by aging populations, innovation in biologics and medical devices, and steady demand for pharmaceuticals and services. ValueSense analysis highlights undervalued healthcare stocks based on intrinsic value calculations, where current market prices trade below estimated fair values, suggesting potential margin of safety for long-term investors. These top stocks to buy now were selected using ValueSense's proprietary methodology, prioritizing high Quality ratings (above 6.0), strong ROIC, robust Free Cash Flow, and positive Revenue growth. Stocks feature significant upside to intrinsic value, diversified across pharmaceuticals, biotech, medtech, and health services. This stock watchlist focuses on companies with FCF margins over 14% where possible, balanced debt profiles, and compelling 1Y returns or recovery potential, making them prime candidates for best value stocks in healthcare.
Featured Stock Analysis
Stock #1: AbbVie Inc. (ABBV)
| Metric | Value |
|---|---|
| Market Cap | $407.0B |
| Quality Rating | 6.4 |
| Intrinsic Value | $301.8 |
| 1Y Return | 29.0% |
| Revenue | $59.6B |
| Free Cash Flow | $20.6B |
| Revenue Growth | 7.4% |
| FCF margin | 34.5% |
| Gross margin | 76.2% |
| ROIC | 12.0% |
| Total Debt to Equity | (2,645.0%) |
Investment Thesis
AbbVie Inc. (ABBV) stands out in the ValueSense analysis with a Quality rating of 6.4 and an intrinsic value of $301.8, indicating substantial undervaluation for long-term portfolio consideration. The company boasts a massive Market Cap of $407.0B, supported by $59.6B in Revenue and exceptional Free Cash Flow of $20.6B, yielding a robust FCF margin of 34.5%. With a Gross margin of 76.2% and Revenue growth of 7.4%, AbbVie demonstrates operational efficiency in its pharmaceutical portfolio, particularly immunology and oncology drugs. Despite a high Total Debt to Equity ratio of 2,645.0%, the ROIC of 12.0% and 29.0% 1Y Return underscore its ability to generate returns, positioning ABBV as a core holding in healthcare stock picks for value-oriented analysis.
This biotech leader's cash generation supports dividends and buybacks, enhancing shareholder value amid sector growth.
Key Catalysts
- Strong FCF of $20.6B enables R&D and acquisitions
- High Gross margin 76.2% reflects pricing power in key drugs
- 7.4% Revenue growth signals pipeline momentum
- 29.0% 1Y Return shows market recognition of stability
Risk Factors
- Elevated Total Debt to Equity (2,645.0%) could pressure in rising rates
- Patent cliffs on blockbusters may impact near-term revenue
- Regulatory scrutiny in pharmaceuticals
Stock #2: UnitedHealth Group Incorporated (UNH)
| Metric | Value |
|---|---|
| Market Cap | $306.8B |
| Quality Rating | 6.2 |
| Intrinsic Value | $626.4 |
| 1Y Return | -33.0% |
| Revenue | $435.2B |
| Free Cash Flow | $17.4B |
| Revenue Growth | 11.8% |
| FCF margin | 4.0% |
| Gross margin | 19.7% |
| ROIC | 19.0% |
| Total Debt to Equity | 78.9% |
Investment Thesis
UnitedHealth Group (UNH) earns a Quality rating of 6.2 from ValueSense, with an intrinsic value of $626.4 far exceeding current levels, highlighting undervaluation in health services. At a Market Cap of $306.8B, it leads with $435.2B Revenue—the highest in this watchlist—and $17.4B Free Cash Flow, though FCF margin is 4.0% due to scale. Revenue growth of 11.8%, ROIC of 19.0%, and Gross margin of 19.7% reflect efficient operations in insurance and care delivery. The -33.0% 1Y Return presents a contrarian opportunity, with Total Debt to Equity at 78.9% manageable for its cash flows, making UNH a diversified anchor in undervalued stocks to buy.
Key Catalysts
- Massive scale with 11.8% Revenue growth
- High ROIC 19.0% drives capital efficiency
- $17.4B FCF supports expansion into value-based care
- Sector tailwinds from healthcare demand
Risk Factors
- Low FCF margin 4.0% vulnerable to cost pressures
- Regulatory risks in managed care
- Recent -33.0% 1Y Return signals volatility
Stock #3: Novartis AG (NVS)
| Metric | Value |
|---|---|
| Market Cap | $265.6B |
| Quality Rating | 6.1 |
| Intrinsic Value | $146.5 |
| 1Y Return | 42.6% |
| Revenue | $55.5B |
| Free Cash Flow | $11.3B |
| Revenue Growth | 12.5% |
| FCF margin | 20.4% |
| Gross margin | 37.2% |
| ROIC | 19.1% |
| Total Debt to Equity | 71.6% |
Investment Thesis
Novartis AG (NVS) scores a Quality rating of 6.1, with intrinsic value at $146.5 signaling upside in global pharma. Market Cap of $265.6B pairs with $55.5B Revenue, $11.3B Free Cash Flow (FCF margin 20.4%), and top-tier 12.5% Revenue growth. ROIC of 19.1% and Gross margin of 37.2% highlight innovation in gene therapy and cardiology, bolstered by 42.6% 1Y Return. Total Debt to Equity at 71.6% is balanced, positioning NVS as a growth play in healthcare stock picks.
Key Catalysts
- Leading 12.5% Revenue growth
- Strong ROIC 19.1% and FCF margin 20.4%
- 42.6% 1Y Return reflects momentum
- Diversified pipeline across therapies
Risk Factors
- Currency risks as international player
- Pipeline dependency on approvals
- Moderate Gross margin 37.2%
Stock #4: Merck & Co., Inc. (MRK)
| Metric | Value |
|---|---|
| Market Cap | $264.7B |
| Quality Rating | 7.3 |
| Intrinsic Value | $115.6 |
| 1Y Return | 7.3% |
| Revenue | $64.2B |
| Free Cash Flow | $13.0B |
| Revenue Growth | 1.7% |
| FCF margin | 20.3% |
| Gross margin | 82.8% |
| ROIC | 30.1% |
| Total Debt to Equity | 79.8% |
Investment Thesis
Merck & Co. (MRK) leads with a Quality rating of 7.3—the highest here—and intrinsic value of $115.6, underscoring value in oncology and vaccines. Market Cap $264.7B supports $64.2B Revenue, $13.0B Free Cash Flow (FCF margin 20.3%), and elite Gross margin of 82.8%. ROIC at 30.1% is exceptional, despite modest 1.7% Revenue growth and 7.3% 1Y Return, with Total Debt to Equity of 79.8%. MRK offers stability in best value stocks portfolios.
Key Catalysts
- Top ROIC 30.1% and Gross margin 82.8%
- Reliable $13.0B FCF
- Keytruda-driven oncology dominance
- Defensive vaccine revenue
Risk Factors
- Slow 1.7% Revenue growth
- Patent expiration risks
- R&D spending pressures
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #5: Novo Nordisk A/S (NVO)
| Metric | Value |
|---|---|
| Market Cap | $231.4B |
| Quality Rating | 6.3 |
| Intrinsic Value | $87.1 |
| 1Y Return | -40.1% |
| Revenue | DKK 315.6B |
| Free Cash Flow | DKK 62.7B |
| Revenue Growth | 16.6% |
| FCF margin | 19.9% |
| Gross margin | 82.0% |
| ROIC | 27.2% |
| Total Debt to Equity | 59.6% |
Investment Thesis
Novo Nordisk (NVO) holds a Quality rating of 6.3, intrinsic value $87.1, in diabetes and obesity treatments. Market Cap $231.4B, Revenue DKK 315.6B, Free Cash Flow DKK 62.7B (FCF margin 19.9%), 16.6% Revenue growth, Gross margin 82.0%, ROIC 27.2%, Total Debt to Equity 59.6%. -40.1% 1Y Return suggests rebound potential in undervalued healthcare stocks.
Key Catalysts
- Highest 16.6% Revenue growth
- Strong ROIC 27.2%, Gross margin 82.0%
- GLP-1 drug demand boom
- Solid FCF generation
Risk Factors
- Sharp -40.1% 1Y Return volatility
- Competition in obesity space
- Currency exposure (DKK)
Stock #6: Thermo Fisher Scientific Inc. (TMO)
| Metric | Value |
|---|---|
| Market Cap | $223.2B |
| Quality Rating | 6.0 |
| Intrinsic Value | $642.5 |
| 1Y Return | 13.4% |
| Revenue | $43.7B |
| Free Cash Flow | $6,111.0M |
| Revenue Growth | 3.2% |
| FCF margin | 14.0% |
| Gross margin | 40.8% |
| ROIC | 8.3% |
| Total Debt to Equity | 69.9% |
Investment Thesis
Thermo Fisher (TMO) rates 6.0 in Quality, intrinsic value $642.5, for life sciences tools. Market Cap $223.2B, Revenue $43.7B, Free Cash Flow $6,111.0M (FCF margin 14.0%), 3.2% Revenue growth, Gross margin 40.8%, ROIC 8.3%, Total Debt to Equity 69.9%. 13.4% 1Y Return adds appeal.
Key Catalysts
- Biopharma services growth
- 13.4% 1Y Return stability
- Recurring revenue model
- M&A potential from FCF
Risk Factors
- Lower ROIC 8.3%
- Cyclical biotech funding
- Slower 3.2% Revenue growth
Stock #7: Abbott Laboratories (ABT)
| Metric | Value |
|---|---|
| Market Cap | $217.2B |
| Quality Rating | 7.1 |
| Intrinsic Value | $176.3 |
| 1Y Return | 10.0% |
| Revenue | $43.8B |
| Free Cash Flow | $6,917.0M |
| Revenue Growth | 6.4% |
| FCF margin | 15.8% |
| Gross margin | 55.0% |
| ROIC | 25.0% |
| Total Debt to Equity | 25.2% |
Investment Thesis
Abbott (ABT) scores Quality rating 7.1, intrinsic value $176.3, in diagnostics and nutrition. Market Cap $217.2B, Revenue $43.8B, Free Cash Flow $6,917.0M (FCF margin 15.8%), 6.4% Revenue growth, Gross margin 55.0%, ROIC 25.0%, low Total Debt to Equity 25.2%. 10.0% 1Y Return supports balance.
Key Catalysts
- High ROIC 25.0%
- Low debt 25.2% enhances flexibility
- Diagnostics growth post-COVID
- Steady 6.4% Revenue growth
Risk Factors
- Nutrition segment competition
- Regulatory hurdles
- Moderate FCF margin
Stock #8: Amgen Inc. (AMGN)
| Metric | Value |
|---|---|
| Market Cap | $176.0B |
| Quality Rating | 6.5 |
| Intrinsic Value | $454.0 |
| 1Y Return | 27.4% |
| Revenue | $36.0B |
| Free Cash Flow | $11.5B |
| Revenue Growth | 10.5% |
| FCF margin | 32.1% |
| Gross margin | 66.1% |
| ROIC | 12.0% |
| Total Debt to Equity | 567.5% |
Investment Thesis
Amgen (AMGN) has Quality rating 6.5, intrinsic value $454.0, in biologics. Market Cap $176.0B, Revenue $36.0B, Free Cash Flow $11.5B (FCF margin 32.1%), 10.5% Revenue growth, Gross margin 66.1%, ROIC 12.0%, Total Debt to Equity 567.5%. Strong 27.4% 1Y Return.
Key Catalysts
- Excellent FCF margin 32.1%
- 10.5% Revenue growth, 27.4% 1Y Return
- Biosimilar expansion
- Dividend aristocrat status
Risk Factors
- High Total Debt to Equity 567.5%
- Biosimilar competition
- Pipeline gaps
Stock #9: Pfizer Inc. (PFE)
| Metric | Value |
|---|---|
| Market Cap | $143.1B |
| Quality Rating | 6.1 |
| Intrinsic Value | $45.9 |
| 1Y Return | -3.8% |
| Revenue | $62.8B |
| Free Cash Flow | $10.4B |
| Revenue Growth | 4.4% |
| FCF margin | 16.5% |
| Gross margin | 69.4% |
| ROIC | 9.8% |
| Total Debt to Equity | 66.3% |
Investment Thesis
Pfizer (PFE) rates 6.1 in Quality, intrinsic value $45.9, post-COVID pivot. Market Cap $143.1B, Revenue $62.8B, Free Cash Flow $10.4B (FCF margin 16.5%), 4.4% Revenue growth, Gross margin 69.4%, ROIC 9.8%, Total Debt to Equity 66.3%. -3.8% 1Y Return offers entry.
Key Catalysts
- Large Revenue base, $10.4B FCF
- Oncology and rare disease pipeline
- High Gross margin 69.4%
- Acquisition strategy
Risk Factors
- -3.8% 1Y Return decline
- COVID revenue drop-off
- Patent losses
Stock #10: Medtronic plc (MDT)
| Metric | Value |
|---|---|
| Market Cap | $122.9B |
| Quality Rating | 6.5 |
| Intrinsic Value | $107.2 |
| 1Y Return | 19.7% |
| Revenue | $34.8B |
| Free Cash Flow | $5,206.0M |
| Revenue Growth | 5.3% |
| FCF margin | 15.0% |
| Gross margin | 62.3% |
| ROIC | 18.9% |
| Total Debt to Equity | N/A |
Investment Thesis
Medtronic (MDT) achieves Quality rating 6.5, intrinsic value $107.2, in medtech. Market Cap $122.9B, Revenue $34.8B, Free Cash Flow $5,206.0M (FCF margin 15.0%), 5.3% Revenue growth, Gross margin 62.3%, ROIC 18.9%, Total Debt to Equity N/A. 19.7% 1Y Return shines.
Key Catalysts
- High ROIC 18.9%
- 19.7% 1Y Return momentum
- Device innovation in cardiology
- Global medtech demand
Risk Factors
- Supply chain vulnerabilities
- Procedure deferrals in downturns
- Debt details unavailable
Portfolio Diversification Insights
These 10 best healthcare stocks create a balanced stock watchlist, with heavy allocation to pharmaceuticals (ABBV, NVS, MRK, NVO, AMGN, PFE ~60%) for innovation and cash flows, medtech (TMO, ABT, MDT ~20%) for devices, and services (UNH ~10%). High ROIC leaders like MRK 30.1% complement growth plays like NVO (16.6% revenue growth). Debt varies—ABT's low 25.2% offsets ABBV/AMGN highs—while average Quality rating ~6.4 ensures quality. Pair high-FCF pharma with UNH for defensive scale, reducing sector-specific risks like regulation.
Market Timing & Entry Strategies
Consider entry on pullbacks to intrinsic value discounts, especially for negative 1Y return stocks like UNH/NVO/PFE amid market rotations. Monitor Q4 earnings for revenue beats; dollar-cost average into leaders like MRK/ABT for stability. Watch Fed rates impacting high-debt names (ABBV, AMGN); favorable healthcare policy could catalyze. Use ValueSense tools for real-time intrinsic updates before positioning.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These top 10 undervalued healthcare stocks were chosen via ValueSense methodology, emphasizing intrinsic value upside, Quality ratings ≥6.0, strong ROIC, FCF margins, and Revenue growth for balanced investment opportunities.
What's the best stock from this list?
Merck (MRK) tops with Quality rating 7.3, 30.1% ROIC, and 82.8% Gross margin, offering elite efficiency; Abbott (ABT) follows at 7.1 with low debt—ideal for ABBV analysis comparables.
Should I buy all these stocks or diversify?
Diversify across subsectors (pharma, medtech, services) to mitigate risks; allocate 10-20% per stock, favoring high intrinsic value gaps like UNH $626.4 for stock watchlist optimization.
What are the biggest risks with these picks?
Key concerns include high debt (ABBV 2,645.0%, AMGN 567.5%), regulatory/patent risks (MRK, PFE), and volatility (-40.1% NVO 1Y return); balance with low-debt ABT.
When is the best time to invest in these stocks?
Target dips below intrinsic values, post-earnings beats, or sector rotations; ongoing healthcare demand supports long-term holds, per ValueSense fundamental analysis.